Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
Meet Laura Cheng. Laura is a nurse. She has acromegaly. She works as a clinical nurse and is currently enrolled in the endocrine program at Duke University. Laura’s connection to this disease gives her a unique perspective and will provide an invaluable resource to her patients. We caught up with Laura a few weeks ago. This is her story.
In our first live-talk session of 2023, we focus on critical topics, including insurance delay trends affecting pituitary medical practices, interesting clinical cases we can learn from, where telemedicine is going after the Covid era, and more commentary from the subjects we covered in our recent “briefing and insights” article.
Today we present an excellent discussion with Dr. Alan Krasner, Chief Medical Officer for Crinetics Pharmaceuticals. Dr. Krasner speaks to PWN about two very important drugs currently under development.
The ongoing debates and nomenclature change and reclassification are apparently over, and adenomas are now referred to as Pit-Net’s (pituitary neuroendocrine tumors). Is this good, bad, or indifferent?
In today’s podcasts, Dr. Blevins talks about the genesis of pseudo Cushing’s syndrome and illustrates a fascinating case of pseudo Cushing’s syndrome due to alcohol ingestion.
What does medical decision-making mean, and what is involved? What are pituitary specialists thinking about when faced with decisions on how to treat a patient? This live talk session aims at answering these tough questions. This podcast will shed some light on what a physician does when making medical decisions. Enjoy!
In this podcast from our “musings series” comes an interesting discussion on lab result targets. This case comes from a hypothyroid patient who wanted to achieve a particular TSH lab result target. In the discussion, Dr. Blevins focuses on how the pituitary works, how lab tests work, and what makes aiming at and achieving a narrow target almost impossible.
Do you ever wonder what happens in the OR after you are wheeled in? We welcome once again our friend and contributor, Manish Aghi, M.D. Ph.D., Attending Neurosurgeon at the California Center for Pituitary Disorders, Professor of Neurological Surgery, and Principal Investigator at UCSF Brain Tumor Research Center. He spent an amazing hour with Dr. Blevins and me, walking us through his work with patients before surgery, his approaches post-surgery, recovery, potential issues, and the many other phases of pituitary surgery.
To continue our focus on pituitary awareness month, this session touches on various issues related to awareness and its importance as a critical factor in reducing the time to diagnosis.
If you didn’t have a chance to hear it live, here’s a podcast from the live talk session from last Thursday with special guest and PWN friend and contributor Pituitary neurosurgeon Dr. Sandeep Kunwar. He joined Dr. Lewis Blevins for a great discussion of the latest in pituitary surgery and disease management.
An informative discussion on the effects of hormones on hair loss, a common occurrence for people dealing with pituitary conditions. In this LIve-talk session, Dr. Blevins discusses the facts and the myths.
On our Live-talk program today, a fascinating, nothing left on the table, discussion about a variety of topics that affect pituitary patients; from access to medication and therapies to problems with social media and misinformation to the complexities of diagnosis and refuting diagnosis to the role of the doctor and the patient to solve many of these challenges.
Today’s podcast focuses on an opportunity to learn about a group of rare diseases that share a common condition with pituitary disease. Histiocytosis or histiocytic disorders are a group of rare diseases that occur when there is an overproduction of white blood cells known as histiocytes that can lead to organ damage and tumor formation. DI impacts almost 50% of Histiocytosis patients and 35% of pituitary patients.